A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression
H Zhao, X Shao, Y Yu, L Huang, NP Amor, K Guo… - npj Vaccines, 2024 - nature.com
H Zhao, X Shao, Y Yu, L Huang, NP Amor, K Guo, C Weng, W Zhao, A Yang, J Hu, H Yang…
npj Vaccines, 2024•nature.comHere we report on the development and comprehensive evaluations of an mRNA vaccine for
chronic hepatitis B (CHB) treatment. In two different HBV carrier mouse models generated by
viral vector-mediated HBV transfection (pAAV-HBV1. 2 and rAAV8-HBV1. 3), this vaccine
demonstrates sufficient and persistent virological suppression, and robust immunogenicity in
terms of induction of strong innate immune activation, high-level virus-specific antibodies,
memory B cells and T cells. mRNA platform therefore holds prospects for therapeutic …
chronic hepatitis B (CHB) treatment. In two different HBV carrier mouse models generated by
viral vector-mediated HBV transfection (pAAV-HBV1. 2 and rAAV8-HBV1. 3), this vaccine
demonstrates sufficient and persistent virological suppression, and robust immunogenicity in
terms of induction of strong innate immune activation, high-level virus-specific antibodies,
memory B cells and T cells. mRNA platform therefore holds prospects for therapeutic …
Abstract
Here we report on the development and comprehensive evaluations of an mRNA vaccine for chronic hepatitis B (CHB) treatment. In two different HBV carrier mouse models generated by viral vector-mediated HBV transfection (pAAV-HBV1.2 and rAAV8-HBV1.3), this vaccine demonstrates sufficient and persistent virological suppression, and robust immunogenicity in terms of induction of strong innate immune activation, high-level virus-specific antibodies, memory B cells and T cells. mRNA platform therefore holds prospects for therapeutic vaccine development to combat CHB.
nature.com
